[go: up one dir, main page]

SI9620040B - Postopek in kristalne oblike 2-metil-tieno-benzodiazepina - Google Patents

Postopek in kristalne oblike 2-metil-tieno-benzodiazepina Download PDF

Info

Publication number
SI9620040B
SI9620040B SI9620040A SI9620040A SI9620040B SI 9620040 B SI9620040 B SI 9620040B SI 9620040 A SI9620040 A SI 9620040A SI 9620040 A SI9620040 A SI 9620040A SI 9620040 B SI9620040 B SI 9620040B
Authority
SI
Slovenia
Prior art keywords
olanzapine
ray powder
polymorph
diffraction pattern
pharmaceutical formulation
Prior art date
Application number
SI9620040A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9620040A (sl
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Eli Lilly And Company
Lilly Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9620040(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company, Lilly Industries Limited filed Critical Eli Lilly And Company
Publication of SI9620040A publication Critical patent/SI9620040A/sl
Publication of SI9620040B publication Critical patent/SI9620040B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
SI9620040A 1995-03-24 1996-03-22 Postopek in kristalne oblike 2-metil-tieno-benzodiazepina SI9620040B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (fr) 1995-03-24 1996-03-22 Formes cristalline de 2-methyl-thieno-benzodiazepine et procede correspondant

Publications (2)

Publication Number Publication Date
SI9620040A SI9620040A (sl) 1998-06-30
SI9620040B true SI9620040B (sl) 2002-02-28

Family

ID=23621056

Family Applications (4)

Application Number Title Priority Date Filing Date
SI9620040A SI9620040B (sl) 1995-03-24 1996-03-22 Postopek in kristalne oblike 2-metil-tieno-benzodiazepina
SI9630636T SI1095941T1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine
SI9630345T SI0733635T1 (en) 1995-03-24 1996-03-22 Crystal forms of a thieno(2,3-B)(1,5) benzodiazepine derivative and process for their preparation
SI9630743T SI1445259T1 (sl) 1995-03-24 1996-03-22 Uporaba kristalnih oblik 2-metil-tienobenzodiazepina

Family Applications After (3)

Application Number Title Priority Date Filing Date
SI9630636T SI1095941T1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine
SI9630345T SI0733635T1 (en) 1995-03-24 1996-03-22 Crystal forms of a thieno(2,3-B)(1,5) benzodiazepine derivative and process for their preparation
SI9630743T SI1445259T1 (sl) 1995-03-24 1996-03-22 Uporaba kristalnih oblik 2-metil-tienobenzodiazepina

Country Status (48)

Country Link
US (1) US5736541A (fr)
EP (3) EP0733635B1 (fr)
JP (1) JPH11502535A (fr)
KR (1) KR100399688B1 (fr)
CN (1) CN1065536C (fr)
AP (1) AP828A (fr)
AR (2) AR010448A1 (fr)
AT (4) AT406771B (fr)
AU (1) AU706471B2 (fr)
BG (1) BG62619B1 (fr)
BR (1) BR9607790A (fr)
CA (1) CA2214005C (fr)
CH (1) CH690579A5 (fr)
CO (1) CO4650278A1 (fr)
CZ (1) CZ292688B6 (fr)
DE (4) DE69636313T2 (fr)
DK (4) DK1445259T3 (fr)
EA (1) EA000149B1 (fr)
EE (1) EE03489B1 (fr)
EG (1) EG23659A (fr)
ES (3) ES2208220T3 (fr)
FI (1) FI973750L (fr)
GB (1) GB2313835B (fr)
HU (1) HU224989B1 (fr)
IL (1) IL117610A (fr)
IS (1) IS1896B (fr)
LT (1) LT4349B (fr)
LU (1) LU90096B1 (fr)
LV (1) LV12018B (fr)
MY (1) MY114701A (fr)
NO (1) NO314663B1 (fr)
NZ (1) NZ306110A (fr)
OA (1) OA10510A (fr)
PA (1) PA8353701A1 (fr)
PE (1) PE44897A1 (fr)
PL (1) PL183723B1 (fr)
PT (3) PT733635E (fr)
RO (1) RO118872B1 (fr)
SE (1) SE9703205D0 (fr)
SI (4) SI9620040B (fr)
SK (1) SK284143B6 (fr)
SV (1) SV1996000031A (fr)
TR (1) TR199701017T1 (fr)
TW (2) TW442488B (fr)
UA (1) UA44765C2 (fr)
WO (1) WO1996030375A1 (fr)
YU (1) YU49478B (fr)
ZA (2) ZA962342B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CA2232559A1 (fr) * 1995-09-29 1997-04-03 Charles Merritt Beasley Jr. Methode de traitement d'un tic chronique
JP2000506528A (ja) * 1996-03-11 2000-05-30 イーライ・リリー・アンド・カンパニー 不眠症の処置方法
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
CZ298198A3 (cs) * 1996-03-25 1999-06-16 Eli Lilly And Company Farmaceutický přípravek
EP0932407A4 (fr) * 1996-03-25 2002-04-24 Lilly Co Eli Technique de traitement de la douleur due a la migraine
WO1997035585A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Methode d'anesthesie
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
HU226167B1 (hu) * 1996-09-23 2008-05-28 Lilly Co Eli Olanzapin-dihidrát D, elõállítása és az azt tartalmazó gyógyszerkészítmények
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
AU6955998A (en) * 1997-04-15 1998-11-11 Eli Lilly And Company Method for providing neuro-protective effects
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
EP1155696B1 (fr) * 1997-04-15 2004-03-03 Eli Lilly And Company Utilisation de l'olanzapine pour la fabrication d'un médicament pour la neuroprotection
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
HU227400B1 (en) * 1998-09-30 2011-05-30 Lilly Co Eli 2-methyl-thieno-benzodiazepine formulation and its use
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
DK1246827T3 (da) * 1999-12-28 2005-05-23 Cipla Ltd Nye polymorfe former af olanzapin
BR0114031A (pt) * 2000-08-31 2003-09-09 Reddy S Lab Ltd Processo para a preparação de hidratos de olanzapina e sua conversão em formas cristalinas de olanzapina
WO2002019998A2 (fr) * 2000-09-08 2002-03-14 Eli Lilly And Company Traitement des prises de poids associees a l'utilisation d'antipsychotiques atypiques
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
AU2002340328A1 (en) * 2001-10-29 2003-05-12 Janet I. Cord Olanzapine dihydrate-ii a process for its preparation and use thereof
CA2471341C (fr) 2001-12-24 2012-01-24 Sun Pharmaceutical Industries Limited Forme cristalline de 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (fr) * 2002-03-01 2003-09-12 University Of South Florida Phases solides multicomposants contentant au moins un principe pharmaceutiquement actif
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
WO2004089313A2 (fr) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Nouvelles formes de l'olanzapine et methodes de traitement associees
WO2004000284A1 (fr) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a dissolution amelioree
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
DE60336226D1 (de) * 2002-05-31 2011-04-14 Sandoz Ag Verfahren zur herstellung von olanzapin form i
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
EP1575962A1 (fr) 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Nouvelles formes cristallines d'olanzapine, procedes pour les preparer et procede pour preparer des formes cristallines d'olanzapine connues
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
DE602004004453T2 (de) * 2003-03-12 2007-11-08 Teva Pharmaceutical Industries Ltd. Stabile pharmazeutische zusammensetzungen mit desloratadin
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
AU2004291043A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
PL1611139T3 (pl) * 2003-12-22 2008-10-31 Teva Pharma Sposób wytwarzania olenzapiny
WO2005070938A1 (fr) 2004-01-27 2005-08-04 Synthon B.V. Sels stables d'olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
ES2303462B1 (es) * 2004-09-06 2009-06-05 Shasun Chemicals And Drugs Limited Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
EP1838716B1 (fr) 2005-01-05 2011-06-01 Eli Lilly And Company Dihydrate d'olanzapine pamoate
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
US20100174066A1 (en) * 2005-03-21 2010-07-08 Venkataraman Sundaram Process for preparing crystalline form i of olanzapine
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (fr) * 2005-08-17 2008-05-14 Synthon B.V. Procede de fabrication d'olanzapine de forme i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (fr) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Nouvelles methodes de synthese de la forme-i de l'olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (fr) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Processus de purification d'olanzapine
AU2011293502B2 (en) 2010-08-23 2015-03-19 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (fr) 2011-05-04 2012-11-15 Zentiva K.S. Composition pharmaceutique d'olanzapine de forme 1 à administration par voie orale
CN107253993B (zh) 2012-08-21 2021-10-22 詹森药业有限公司 奥氮平的抗体及其用途
EP2888284B1 (fr) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Anticorps dirigés contre des haptènes de rispéridone et leur utilisation
TR201910347T4 (tr) * 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
KR20240130825A (ko) 2022-01-20 2024-08-29 테바 파마슈티컬스 인터내셔널 게엠베하 올란자핀, 이의 조성물 및 이의 사용 방법
AU2024208071A1 (en) 2023-01-10 2025-06-12 Medincell Sa Olanzapine compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (fr) 1977-07-20 1981-03-10 George K. E. Gregory Emballages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
EP0582368B1 (fr) * 1992-05-29 2001-01-24 Eli Lilly And Company Limited Dérivés de thienobenzodiazépine pour le traitement des troubles du système nerveux central
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
IL117610A (en) 2001-08-26
EP0733635A1 (fr) 1996-09-25
EP0733635B1 (fr) 2001-08-16
AP828A (en) 2000-04-28
CZ300097A3 (en) 1997-12-17
PT733635E (pt) 2001-12-28
CO4650278A1 (es) 1998-09-03
PT1095941E (pt) 2004-02-27
DE69630324D1 (de) 2003-11-13
ZA962344B (en) 1997-09-22
HUP9802824A3 (en) 2000-01-28
SI9620040A (sl) 1998-06-30
DE19681286T1 (de) 1998-04-02
ES2159346T3 (es) 2001-10-01
ES2208220T3 (es) 2004-06-16
SK121897A3 (en) 1998-03-04
SE9703205L (sv) 1997-09-05
EP1445259A1 (fr) 2004-08-11
HUP9802824A2 (hu) 1999-06-28
EP1095941B1 (fr) 2003-10-08
ATA902196A (de) 2000-01-15
DK108997A (da) 1997-11-12
DE69630324T2 (de) 2004-07-29
GB9719819D0 (en) 1997-11-19
PE44897A1 (es) 1997-10-22
EP1095941A1 (fr) 2001-05-02
AR002719A1 (es) 1998-04-29
PL183723B1 (pl) 2002-07-31
CN1179160A (zh) 1998-04-15
DE69614426D1 (de) 2001-09-20
HK1013988A1 (en) 1999-09-17
LV12018A (lv) 1998-04-20
SK284143B6 (sk) 2004-10-05
SI1445259T1 (sl) 2006-10-31
SI1095941T1 (en) 2003-12-31
SV1996000031A (es) 1998-03-27
LT4349B (lt) 1998-05-25
KR19980703188A (ko) 1998-10-15
CN1065536C (zh) 2001-05-09
SI0733635T1 (en) 2002-06-30
AU706471B2 (en) 1999-06-17
FI973750A0 (fi) 1997-09-22
IS1896B (is) 2003-10-20
EG23659A (en) 2007-03-26
ATE331719T1 (de) 2006-07-15
IL117610A0 (en) 1996-07-23
CA2214005A1 (fr) 1996-10-03
GB2313835B (en) 1998-09-16
ATE251627T1 (de) 2003-10-15
AU5427996A (en) 1996-10-16
CH690579A5 (de) 2000-10-31
LV12018B (en) 1998-09-20
LT97148A (lt) 1998-01-26
DE69614426T2 (de) 2002-05-23
NZ306110A (en) 1998-09-24
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
DK1095941T3 (da) 2004-02-16
DE69636313T2 (de) 2007-05-31
FI973750A7 (fi) 1997-09-22
FI973750L (fi) 1997-09-22
UA44765C2 (uk) 2002-03-15
AT406771B (de) 2000-08-25
BG62619B1 (bg) 2000-03-31
PL322501A1 (en) 1998-02-02
NO314663B1 (no) 2003-04-28
US5736541A (en) 1998-04-07
NO974365L (no) 1997-09-22
EE03489B1 (et) 2001-08-15
YU17796A (sh) 1999-03-04
ES2266719T3 (es) 2007-03-01
IS4564A (is) 1997-09-22
LU90096B1 (fr) 1997-07-22
TW513432B (en) 2002-12-11
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
OA10510A (en) 2002-04-24
EA000149B1 (ru) 1998-10-29
EP1445259B1 (fr) 2006-06-28
ZA962342B (en) 1997-09-22
BG101900A (en) 1999-03-31
MX9707183A (es) 1997-11-29
JPH11502535A (ja) 1999-03-02
KR100399688B1 (ko) 2004-02-18
DK0733635T3 (da) 2001-10-08
BR9607790A (pt) 1998-07-07
MY114701A (en) 2002-12-31
EE9700232A (et) 1998-04-15
DE69636313D1 (de) 2006-08-10
TW442488B (en) 2001-06-23
CA2214005C (fr) 2001-07-03
HU224989B1 (en) 2006-05-29
DK1445259T3 (da) 2006-10-16
EA199700262A1 (ru) 1998-02-26
ATE204280T1 (de) 2001-09-15
YU49478B (sh) 2006-05-25
CZ292688B6 (cs) 2003-11-12
SE9703205D0 (sv) 1997-09-05
GB2313835A (en) 1997-12-10
NO974365D0 (no) 1997-09-22
WO1996030375A1 (fr) 1996-10-03
TR199701017T1 (xx) 1998-01-21
RO118872B1 (ro) 2003-12-30

Similar Documents

Publication Publication Date Title
SI9620040B (sl) Postopek in kristalne oblike 2-metil-tieno-benzodiazepina
US5420145A (en) Carboxylic acid derivative
SE452322B (sv) Kristallina 1,1-dioxopenicillanoyloximetyl-6-(d-alfa-amino-alfa-fenylacetamido) penicillanat-p-toluensulfonat-hydrat och farmaceutiska kompositioner derav
HUT67289A (en) Benzimidazole and pyridoimidazole derivatives, pharmaceutical compositions containing them and process for their production
JPH01226818A (ja) アリールアミドアザビシクロアルカン類およびアリールチオアミドアザビシクロアルカン類からなる記憶力増進剤または記憶障害治療剤
HUT70194A (en) Quinoline- or quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
DE69219807D1 (de) Thienopyridinderivate und diese enthaltende pharmazeutische Zubereitungen
HUT52099A (en) Process for producing antiviral tetrahydroimidazo/1,4/benzodiazepin-2-one derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT55397A (en) Process for producing mevalonic acid derivatives comprising thienopyridine ring and pharmaceutical compositions containing such active ingredient
AU2004318214B2 (en) Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
TW384285B (en) Pharmaceutical composition containing quinoline or quinazoline derivatives and novel derivatives therefor
KR910002437A (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합성질의 조성물
AU7817087A (en) 2-(thio-linked)-pyridine-5-(4,5-dihydro-2-oxazolyl)-(thieno( 2,3-d)-imidazoles and -benzimidazoles), a process for their preparation, and their use
HU895830D0 (en) Process for the preparation of 1,2,3,4-tetrahydro-1,9-acridine-diamines and pharmaceutical compositions containing said compounds
JPH09208496A (ja) Ｌｈ−ｒｈ拮抗物質含有組成物
ZA933455B (en) Thiochroman compounds, processes for the preparation thereof and pharmaceutical compositions containing them
EP0100815B1 (fr) N-(1,3-dithiolan-2-ylidène)anilines et leur application comme agents anti-inflammatoires et anti-asthmatiques
WO2006013085A1 (fr) 4-dérivés de benzoylalanine substitués par sulfonyl utiles en tant qu’inhibiteurs d’aminotransférase kynurénine
US5326782A (en) Salts derived from 26-(dialkylaminoalkylsulphonyl)pristinamycin IIB
EP0046990A2 (fr) Acides halo-2-alkyl-4-dihydro-4,7-oxo-7-thièno(3,2-b)pyridincarboxyliques, leurs sels, leur application thérapeutique et intermédiaires
HUT46911A (en) Process for production of medically applicable acid additional salts of derivatives of new nitrogen-arylmetoxi-tiophene
KR100563455B1 (ko) 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
JPS6335579A (ja) 含硫ベンゾキサジノリフアマイシン誘導体
KR20070023185A (ko) Ｓ-(＋)-클로피도그렐 헤미나파디실레이트 염 및 그의제조방법
EP0294292A3 (en) Derivative of benzoûb¨thiophene-7-carboxylic acid, process for its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20141104